We maintain several equity incentive plans under which we may grant incentive stock options, non-qualified stock options, stock bonuses, restricted stock awards, restricted stock units and stock appreciation rights to employees (including officers), non-employee directors and consultants.

We account for stock-based compensation by recording the estimated fair value of stock-based awards granted as compensation expense over the vesting period, net of estimated forfeitures. Stock-based compensation expense is attributed to earnings using a straight-line method. We estimate forfeitures of stock-based awards based on historical experience and expected future activity.

The fair value of restricted stock awards and units is measured based on the closing price of our common stock on the date of grant. The fair value of stock option grants is estimated on the date of grant using the Black-Scholes option pricing model.

Total stock-based compensation expense is recognized on our condensed consolidated statements of loss as follows (in thousands):


	Three Months Ended
	May 2, 2026		May 3, 2025
Selling, general and administrative expenses	$	1,562	$	1,454
Cost of goods sold		462		374
Total stock-based compensation expense	$	2,024	$	1,828

At May 2, 2026, there was $15.4 million of total unrecognized compensation cost related to unvested stock options, restricted stock awards and restricted stock units. This cost has a weighted-average remaining recognition period of 1.4 years.

The following table summarizes restricted stock awards and restricted stock units, collectively defined as “restricted equity awards” (in thousands, except grant date weighted-average fair value):


	Restricted Stock Awards/Units			Grant Date Weighted- Average Fair Value		Intrinsic Value
Outstanding at January 31, 2026		916		$	15.57
Granted		308			21.73
Vested		(307	)		17.17
Forfeited		(11	)		15.24
Outstanding at May 2, 2026		906		$	17.12	$	22,081

We had 0.7 million stock options outstanding at May 2, 2026 with a grant date weighted average exercise price of $19.77 and 0.6 million stock options outstanding at January 31, 2026 with a grant date weighted average exercise price of $19.35.